Multiple Myeloma Research Foundation (MMRF) Launches Linda Rodgers Emory Fund for Accelerating Immune Therapy in Multiple Myeloma

Multiple Myeloma Research Foundation's picture
Printer-friendly versionPrinter-friendly version

Ms. Rodgers Emory Donates $1M to Support the “MMRF Immune Therapy Network of Excellence”

Norwalk, CT — June 25, 2014

The Multiple Myeloma Research Foundation (MMRF) announced today the generous donation of $1 million by Linda Rodgers Emory, a longtime supporter of the MMRF and recognized philanthropist. The Linda Rodgers Emory Fund for Accelerating Immune Therapy in Multiple Myeloma will urgently advance a pipeline of immunotherapeutic agents to benefit myeloma patients and enable critical research into the basic biology and mechanisms of immune response in myeloma.

I made this gift to the MMRF to help build and support the best portfolio of immunotherapeutic agents possible,” said Ms. Emory, a multiple myeloma patient. “I am confident that the MMRF will assemble the best scientists and researchers from around the world to focus on this exciting area of cancer research and work diligently to speed clinical trials of promising new approaches to benefit all multiple myeloma patients.”

Although it is not entirely clear how immunotherapy treats cancer, it is thought to stop or slow the growth of cancer cells, or stop cancer from spreading to other parts of the body, helping the immune system increase its effectiveness at eliminating cancer cells. Tremendous strides are being made in other cancers using these types of approaches, including trials recently presented at the Annual American Society of Clinical Oncology (ASCO) Meeting. This funding will be used to rapidly advance trials into the clinic and to support activities of the MMRF Myeloma Immune Therapy Network of Excellence.

“Linda Rodgers Emory has provided profound philanthropic leadership to advancing myeloma research and drug development over the years to which we are extremely grateful,” said Kathy Giusti, Founder and CEO of the MMRF. “This contribution will help us build the most robust pipeline of immunotherapeutic agents for myeloma, and will allow us to build collaborations with experts in immune biology in myeloma and in other cancers.”

About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised $250 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit:

Copy this html code to your website/blog to embed this press release.


Post new comment

11 + 1 =

To prevent automated spam submissions leave this field empty.
Page execution time was 510.05 ms.

Memory usage:

Memory used at: devel_init()=2.13 MB, devel_shutdown()=22.56 MB.